An open study to assess the acceptability and effectiveness of miconazole 1,200 mg single ovule in the treatment of acute vaginal candidosis.
The efficacy and acceptability of a single dose 'ovule' formulation of miconazole in the treatment of acute vaginal candidosis has been assessed in 42 patients attending a GU clinic. The signs and symptoms of vaginal candidosis were assessed by the investigator at an initial visit, and at seven and 28 days post-treatment. A high vaginal swab was taken at each visit, for routine microbiology. Patients also rated their symptoms daily for seven days post-treatment. The cure rate at Day 7 was approximately 88 per cent, with the recurrence rate at Day 28 estimated as 16 per cent of those cured. All patients found the single dosage formulation easy to use, and the majority thought the ovule effective as a treatment for their vaginal candidosis.